ZIM Laboratories Q1 FY27: Revenue rose, margins fell as costs and compliance stayed in focus

Total operating income was INR 942 million (up 31.2% YoY) as per the income statement in the investor presentation.

Management attributed the lower EBITDA margin (3.7%) to higher employee costs from leadership strengthening, increased utilities and power/fuel costs, and consulting/audit related costs linked to EU-GMP remediation activities.

Management stated the EU-GMP reinspection (May 2026) is completed and the company is awaiting the final inspection report. A CAPA plan is prepared based on the draft and will be submitted after the final report is received.

The company allocated INR 82 million to R&D in Q1 FY27, stated as 8.7% of total operating income, including INR 34 million toward BE studies and regulatory filings.

Exports accounted for 84% of revenue in Q1 FY27, with export revenue of INR 792 million as shown in the business mix slide.

In Q1 FY27, pharma revenue was INR 673 million (72% mix) and nutraceutical revenue was INR 168 million (28% mix), as per the mix table in the presentation.

The CFO stated total debt was about INR 145.2 crore as of 30 June 2026 and that borrowing cost was below 10%. Management said it aims to improve cash flows through better collections and inventory control.